H. Lundbeck A/s

Forest Laboratories Holdings Limited

Merck Sharp + Dohme Corp.

Schering Corporation

Merz Pharma Gmbh & Co Kgaa

Troels Volsgaard Christensen

Sebastian P. Assenza

Shashank Mahashabde

Michiel Onne Elema

Lene Andresen

Ken Liljegren

Mahendra G Dedhiya

Niranjan Rao

Wattanaporn Abramowitz

Suneel K Rastogi

Joel A Sequeira

David Hamilton Harris

Bernhard Hauptmeier

Erhard Seiller

Antonia Periclou

Sebastian P Assenza

Stefan Sharpe

Yan Yang

Anshu Goel

The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions. following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment.

Modified release formulations of memantine oral dosage forms

A liquid suspension comprising an antifungally effective amount of the micronized compound represented by the chemical structural formula I: at least one thickening agent, a non-ionic surfactant, and a pharmaceutically acceptable liquid carrier is disclosed.

Antifungal composition with enhanced bioavailability

Crystalline particles of escitalopram oxalate with a particle size of at least 40 &#x3bc;m is disclosed. Method for the manufacture of said crystalline particles and pharmaceutical compositions comprising said crystalline particles are also disclosed.

Crystalline composition containing escitalopram

Growing community of inventors

Kendall Park, NJ, United States of America

Shashank Mahashabde